The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute
myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal …

Acute myeloid leukaemia (AML) is a heterogeneous disease that is, in general, associated
with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that …

We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent
relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for
patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) …

Abstract Purpose of Review This review aims to summarize the pathophysiology, clinical
presentation, and management of acute myeloid leukemia (AML) with FMS-like tyrosine …

PURPOSE Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or
refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of …

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally
associated with poor prognosis. Allogeneic hematopoietic cell transplantation (alloHCT) …

FLT 3 mutations are present in about one‐third of patients with acute myeloid leukemia
(AML). Several FLT 3 inhibitors have been used in clinical trials, and these include …

Acute myeloid leukemia (AML) with FLT3-mutation carries a poor prognosis, and allogeneic
stem cell transplantation (allo-SCT) is recommended at first complete remission (CR1). We …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are detected in approximately 30%
of acute myeloid leukemia (AML). The high frequency of FLT3 mutations, along with their …